

Factorial ANOVA: follow-up tests

Week 10

Example Data

- fictitious blood pressure drug trial
- DV is **bloodpressure** (lower is better)
- IVs: **biofeedback** (2 levels) and **drug** (3 levels)

```

1 library(tidyverse)
2 bpdata <- read_csv(url("https://www.gribblelab
3                       col_types="nff"))
4 bpdata

```

```

# A tibble: 30 × 3
  bloodpressure biofeedback drug
  <dbl> <fct> <fct>
1     188 present absent
2     183 present absent
3     198 present absent
4     179 present absent
5     193 present absent
6     186 absent present
7     191 absent present
8     190 absent present
9     181 absent present
10    176 absent present
# i 20 more rows

```

► Code

```

# A tibble: 6 × 5
# Groups:   biofeedback [2]
  biofeedback drug meanbp se n
  <fct> <fct> <dbl> <dbl> <int>
1 present absent 188. 3.40 5
2 present present 168. 3.83 5
3 present highdose 162. 5.40 5
4 absent absent 190. 3.54 5
5 absent present 185. 2.82 5
6 absent highdose 185. 1.52 5

```

► Code




Example Data

- we conducted a 2-way factorial ANOVA

```
1 my.anova <- aov(bloodpressure ~ biofeedback * drug,
2                 data = bpdata)
3 summary(my.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- significant main effect of biofeedback,
 $F(1,24)=22.15$, $p=8.76e-05$
- significant main effect of drug,
 $F(2,24)=10.77$, $p=.00046$
- significant biofeedback x drug interaction,
 $F(2,24)=4.66$, $p=.01945$



- what are our next steps?

2x2 ANOVA Follow-up Tests

- If A x B interaction is **not** significant—follow up main effects
 - is main effect of A significant?
 - Yes: conduct pairwise post-hoc tests for marginal means of A
 - No: do nothing
 - is main effect of B significant?
 - Yes: conduct pairwise post-hoc tests for marginal means of B
 - No: do nothing

2x2 ANOVA Follow-up Tests

- If A x B interaction is significant:
 - test the **simple main effect** of A within each level of B
 - (or if you prefer, the **simple main effect** of B within each level of A)
 - like doing a series of one-way ANOVAs on A, one for each level of B
- for each simple main effect that is significant,
 - conduct pairwise post-hoc tests on levels of A within that level of B


2x2 ANOVA Follow-up Tests

- sometimes researchers bypass the simple main effects tests
 - go directly to pairwise post-hoc tests to investigate the interaction effect
- There are differing opinions on whether this is ok
 - some say it is not ok, because the simple main effects are there to protect against Type-I error
 - others say it is ok, as long as the pairwise posthoc tests are properly corrected for Type-I error

2x2 ANOVA Follow-up Tests

- let's assume for now that if there is a significant interaction effect,
 - we will do simple main effects tests first
 - then pairwise post-hoc tests on the significant simple main effects
- let's look at some examples of different scenarios

Example 1



3x2 ANOVA

Drug(3) x Sex(2)


Drug main effect : $p < .05$

Sex main effect : $p > .05$

Drug x Sex interaction : $p > .05$


Follow-up: Drug Main Effect

(averaged over Sex)



pairwise posthoc tests

Example 2



3x2 ANOVA

Drug(3) x Sex(2)


Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p > .05$

Follow-up: Drug Main Effect

(averaged over Sex)




pairwise posthoc tests

Sex main effect
no more needed!



Example 3



3x2 ANOVA

Drug(3) x Sex(2)

Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p < .05$


Simple main effect of Drug
within male

(one-way ANOVA)

↳ if omnibus $p < .05$

↳ pairwise posthoc tests

Example 3



3x2 ANOVA

Drug(3) x Sex(2)


Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p < .05$


Simple main effect of Drug
within female

(one way ANOVA) $p < .05$ then:



post hoc
pairwise
tests

Example 3



3x2 ANOVA

Drug(3) x Sex(2)


Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p < .05$

OR: Go Directly to
Pairwise Posthoc Tests
=> and correct for
Type-I error

Example 3



3x2 ANOVA

Drug(3) x Sex(2)


Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p < .05$

OR: Go Directly to
Pairwise Posthoc Tests
=> and correct for
Type-I error

Example 3



3x2 ANOVA

Drug(3) x Sex(2)


Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p < .05$

OR: Go Directly to
Pairwise Posthoc Tests
=> and correct for
Type-I error

Example 3



3x2 ANOVA

Drug(3) x Sex(2)

Drug main effect : $p < .05$

Sex main effect : $p < .05$

Drug x Sex interaction : $p < .05$

OR: Go Directly to
Pairwise Posthoc Tests
=> and correct for
Type-I error

Following up a Main Effect in R


	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- for purposes of demonstration let's pretend for now that the biofeedback x drug interaction is not significant
- let's follow up the main effect of drug
- marginal means for the Drug factor:

```
1 library(emmeans)
2 (drugMM <- emmeans(my.anova, specs = ~ drug))
```

drug	emmean	SE	df	lower.CL	upper.CL
absent	189	2.55	24	184	194
present	177	2.55	24	171	182
highdose	173	2.55	24	168	178

Results are averaged over the levels of: biofeedback
Confidence level used: 0.95



```
1 pairs(drugMM, adjust="tukey")
```

contrast	estimate	SE	df	t.ratio	p.value
absent - present	12.5	3.61	24	3.464	0.0055
absent - highdose	15.9	3.61	24	4.406	0.0005
present - highdose	3.4	3.61	24	0.942	0.6199

Results are averaged over the levels of: biofeedback
P value adjustment: tukey method for comparing a family of 3 estimates

Following up a Main Effect in R


	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- for purposes of demonstration let's pretend for now that the biofeedback x drug interaction is not significant
- let's follow up the main effect of drug
- marginal means for the Drug factor:

```
1 library(emmeans)
2 (drugMM <- emmeans(my.anova, specs = ~ drug))
```

drug	emmean	SE	df	lower.CL	upper.CL
absent	189	2.55	24	184	194
present	177	2.55	24	171	182
highdose	173	2.55	24	168	178

Results are averaged over the levels of: biofeedback
Confidence level used: 0.95



```
1 pairs(drugMM, adjust="holm")
```

contrast	estimate	SE	df	t.ratio	p.value
absent - present	12.5	3.61	24	3.464	0.0040
absent - highdose	15.9	3.61	24	4.406	0.0006
present - highdose	3.4	3.61	24	0.942	0.3558

Results are averaged over the levels of: biofeedback
P value adjustment: holm method for 3 tests

Following up a Main Effect in R


	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- for purposes of demonstration let's pretend for now that the biofeedback x drug interaction is not significant
- let's follow up the main effect of biofeedback
- marginal means for the biofeedback factor:

```
1 library(emmeans)
2 (biofeedbackMM <- emmeans(my.anova, specs = ~
```

biofeedback	emmean	SE	df	lower.CL	upper.CL
present	173	2.08	24	168	177
absent	187	2.08	24	182	191

Results are averaged over the levels of: drug
Confidence level used: 0.95



- we don't need any more tests, since there are only 2 groups
- we can simply refer to the F test of biofeedback in the ANOVA table

Following up a Main Effect in R


	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- for purposes of demonstration let's pretend for now that the biofeedback x drug interaction is not significant
- let's follow up the main effect of biofeedback
- marginal means for the biofeedback factor:

```
1 library(emmeans)
2 (biofeedbackMM <- emmeans(my.anova, specs = ~
```

biofeedback	emmean	SE	df	lower.CL	upper.CL
present	173	2.08	24	168	177
absent	187	2.08	24	182	191

Results are averaged over the levels of: drug
Confidence level used: 0.95



- BTW: an F-test with 1 numerator df is equivalent to a t-test
- $F = t^2$
- $F(1,24)=22.15$ is equivalent to $t(24)=4.71$


Following up an Interaction in R

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- we will test the **simple main effect of drug** for each level of biofeedback
- within “Absent” biofeedback:

```
1 bpdata_absent <- bpdata %>%
2   filter(biofeedback == "absent")
3 absent.anova <- aov(bloodpressure ~ drug,
4   data = bpdata_absent)
5 summary(absent.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	88.4	44.2	1.166	0.345
Residuals	12	454.8	37.9		



- no simple main effect in “Absent”,
 $F(2, 12) = 1.17$, $p = 0.345$


Following up an Interaction in R

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- we will test the **simple main effect of drug** for each level of biofeedback
- within “Present” biofeedback:

```
1 bpdata_present <- bpdata %>%  
2   filter(biofeedback == "present")  
3 present.anova <- aov(bloodpressure ~ drug,  
4   data = bpdata_present)  
5 summary(present.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	1921	960.3	10.4	0.0024
Residuals	12	1108	92.3		



- yes simple main effect in “Present”,
 $F(2,12)=10.4$, $p=.0024$
- now we need to follow up the simple main effect of **drug** in **biofeedback “Present”**

Following up an Interaction in R

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

- simple main effect of drug within biofeedback present:

```
1 bpdata_present <- bpdata %>%
2   filter(biofeedback == "present")
3 present.anova <- aov(bloodpressure ~ drug,
4   data = bpdata_present)
5 summary(present.anova)
```


	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	1921	960.3	10.4	0.0024
Residuals	12	1108	92.3		

- drug marginal means: biofeedback present

```
1 (drugSME <- emmeans(present.anova, specs = ~ d
```

drug	emmean	SE	df	lower.CL	upper.CL
absent	188	4.3	12	179	198
present	168	4.3	12	159	178
highdose	162	4.3	12	152	171

Confidence level used: 0.95



```
1 pairs(drugSME, adjust="holm")
```

contrast	estimate	SE	df	t.ratio	p.value
absent - present	19.8	6.08	12	3.258	0.0137
absent - highdose	26.7	6.08	12	4.394	0.0026
present - highdose	6.9	6.08	12	1.135	0.2785

P value adjustment: holm method for 3 tests

Following up an Interaction in R

- notice the ANOVA tables for the full ANOVA and for the simple main effect test:

```
1 summary(my.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

```
1 summary(present.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	1921	960.3	10.4	0.0024
Residuals	12	1108	92.3		

- error term (**Residuals**) for full ANOVA is smaller than for simple main effect test
- the **Residuals** df is way larger because it uses the whole dataset
- the full ANOVA **Residuals** is also a more accurate estimate since it uses more data—it's a **pooled** estimate of within-group variability

- some researchers prefer to use the **Residuals** from the full ANOVA when performing simple main effects tests—a customized F-test using **Residuals** term from the full ANOVA

```
1 (F_sme <- 960.3 / 65.1)
```

```
[1] 14.75115
```

```
1 (p_sme <- pf(F_sme, 2, 24, lower.tail = FALSE))
```

```
[1] 6.638425e-05
```

- we end up with a larger F and a smaller p
- it is a statistically more powerful test

Following up an Interaction in R

```
1 summary(my.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

```
1 summary(present.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	1921	960.3	10.4	0.0024
Residuals	12	1108	92.3		

- a customized F-test using the `Residuals` from the full ANOVA

```
1 (F_sme <- 960.3 / 65.1)
```

```
[1] 14.75115
```

```
1 (p_sme <- pf(F_sme, 2, 24, lower.tail = FALSE))
```

```
[1] 6.638425e-05
```

- an argument against this approach is that when there is a possibility of a violation of homogeneity of variance, it is better to perform simple main effects tests on each subset of data (literally a one-way ANOVA on each subset of data)
- this is because the pooled `Residuals` from the full ANOVA are not a good estimate of the error term for each subset of data
- some researchers prefer the “one-way ANOVAs using subsets of the data” approach always, to avoid the possibility of inhomogeneity of variance affecting the results

Following up an Interaction in R

```
1 summary(my.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
biofeedback	1	1442.2	1442.2	22.150	8.76e-05
drug	2	1401.8	700.9	10.765	0.00046
biofeedback:drug	2	607.3	303.6	4.664	0.01945
Residuals	24	1562.6	65.1		

```
1 (MM <- emmeans(my.anova, specs = ~ biofeedback
```

biofeedback	drug	emmean	SE	df	lower.CL	upper.CL
present	absent	188	3.61	24	181	196
absent	absent	190	3.61	24	183	197
present	present	168	3.61	24	161	176
absent	present	185	3.61	24	177	192
present	highdose	162	3.61	24	154	169
absent	highdose	185	3.61	24	177	192

Confidence level used: 0.95

```
1 pairs(MM, adjust="holm", simple="drug")
```

```
biofeedback = present:
contrast      estimate  SE df t.ratio p.value
absent - present    19.800  5.1 24   3.880  0.0014
absent - highdose   26.698  5.1 24   5.232  0.0001
present - highdose    6.898  5.1 24   1.352  0.1891
```

```
biofeedback = absent:
contrast      estimate  SE df t.ratio p.value
absent - present    5.200  5.1 24   1.019  0.9552
absent - highdose    5.098  5.1 24   0.999  0.9552
present - highdose  -0.102  5.1 24  -0.020  0.9842
```

P value adjustment: holm method for 3 tests

- compare to our pairwise comparisons of our one-way ANOVA

```
1 bpdata_present <- bpdata %>%
2   filter(biofeedback == "present")
3 present.anova <- aov(bloodpressure ~ drug,
4   data = bpdata_present)
5 summary(present.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	1921	960.3	10.4	0.0024
Residuals	12	1108	92.3		

```
1 (drugSME <- emmeans(present.anova, specs = ~ d
```

drug	emmean	SE	df	lower.CL	upper.CL
absent	188	4.3	12	179	198
present	168	4.3	12	159	178
highdose	162	4.3	12	152	171

Confidence level used: 0.95

```
1 pairs(drugSME, adjust="holm")
```

```
contrast      estimate  SE df t.ratio p.value
absent - present    19.8  6.08 12   3.258  0.0137
absent - highdose   26.7  6.08 12   4.394  0.0026
present - highdose    6.9  6.08 12   1.135  0.2785
```

P value adjustment: holm method for 3 tests

Following up an Interaction in R

- So what should you actually do?
- should you do simple main effects tests?
 - should you use a “one-way ANOVA on each subset of data” approach?
 - or a custom F-test with numerator from one-way ANOVA and denominator from full ANOVA?
- jump directly to pairwise tests?
 - using `emmeans()` and `pairs()` with `adjust=...`

Following up an Interaction in R

- So what should you actually do?
- the answer will depend upon many things
 - your own opinion about the best approach given your understanding of the tradeoffs
 - your research discipline's conventions
 - your lab/supervisor's conventions
- pick an approach you believe in and understand how to defend/explain it

Following up an Interaction in R

- So what should you actually do?
- try your best to have a dataset such that it doesn't matter which approach you take, the decision/conclusion will be the same (a nice position to be in)

Following up an Interaction in R

- What do I do?
- I jump directly to pairwise tests (corrected for Type-I error, usually with Holm's method)
- I believe the omnibus interaction test provides good initial protection from Type-I error, and this combined with the additional Type-I error correction used for the pairwise tests gives me good protection overall


Assumptions of Factorial ANOVA

- just like one-way ANOVA:
- **normality**
 - shapiro-wilk test
- **homogeneity of variance**
 - levene's test
- **independence**
 - random assignment
 - no repeated measures

Normality Assumption

```
1 qqnorm(y=residuals(my.anova),pch=16)  
2 qqline(y=residuals(my.anova),lty=2)
```

Normal Q-Q Plot



Normality Assumption

```
1 shapiro.test(residuals(my.anova))
```

```
Shapiro-Wilk normality test
```

```
data: residuals(my.anova)
```

```
W = 0.96412, p-value = 0.3928
```

- $p > .05$ so no violation of normality assumption

Homogeneity of Variance Assumption

```
1 library(car)
2 leveneTest(bloodpressure ~ biofeedback * drug, data=bpdata)
```

```
Levene's Test for Homogeneity of Variance (center = median)
      Df F value Pr(>F)
group  5  1.2079 0.3355
      24
```

- $p > .05$ so no violation of homogeneity of variance assumption

3-Way Factorial ANOVA

- 3-way factorial ANOVA is a generalization of 2-way factorial ANOVA
- it is used when there are 3 factors, for example:
- **factor A:** Drug: 3 levels (e.g. placebo, low dose, high dose)
- **factor B:** Sex: 2 levels (e.g. female, male)
- **factor C:** Age: 3 levels (e.g. infant, young, old)
- **DV:** memory score (higher is better)

3-Way Factorial ANOVA

```
1 memdata <- read_csv(url("https://www.gribblelab.org/2812/data/mem_data3.csv"), col_types="nfff")
```

```
1 memdata_means <- memdata %>%
2   group_by(drug, sex, age) %>%
3   summarise(meanmem = mean(memory),
4             se       = sd(memory)/sqrt(n()),
5             n        = n())
6 memdata_means
```


```
# A tibble: 18 × 6
# Groups:   drug, sex [6]
  drug      sex    age  meanmem    se    n
  <fct>    <fct> <fct>    <dbl> <dbl> <int>
1 Placebo  Male    infant   100.  0.982    5
2 Placebo  Male    young   105.  0.823    5
3 Placebo  Male    old     109.  0.459    5
4 Placebo  Female  infant   99.5  0.688    5
5 Placebo  Female  young   106.  0.884    5
6 Placebo  Female  old     110.  0.667    5
7 Low Dose Male    infant   101.  1.20     5
8 Low Dose Male    young   106.  0.795    5
9 Low Dose Male    old     110.  0.953    5
10 Low Dose Female  infant   105.  0.546    5
11 Low Dose Female  young   111.  1.16     5
12 Low Dose Female  old     115.  0.684    5
13 High Dose Male    infant   99.3  0.696    5
14 High Dose Male    young   106.  0.824    5
15 High Dose Male    old     110.  1.08     5
16 High Dose Female  infant   111.  1.08     5
17 High Dose Female  young   113.  1.05     5
18 High Dose Female  old     120.  0.551    5
```

- **factor A:** Drug: 3 levels (e.g. placebo, low dose, high dose)
- **factor B:** Sex: 2 levels (e.g. female, male)
- **factor C:** Age: 3 levels (e.g. infant, young, old)
- **DV:** memory score (higher is better)
- $3 \times 2 \times 3 = 18$ groups (sometimes called ‘cells’)
- “between subjects” ANOVA: different participants in each group
- 5 participants per group
- $18 \times 5 = 90$ participants total

3-Way Factorial ANOVA

► Code


Memory Drug Trial



3-Way Factorial ANOVA


- 3-way ANOVA tests 7 (!!) omnibus effects:
 - three main effects
 - three 2-way interactions
 - one 3-way interaction

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	384.7	192.4	51.148	1.51e-14
sex	1	570.4	570.4	151.656	< 2e-16
age	2	1399.9	699.9	186.113	< 2e-16
drug:sex	2	356.6	178.3	47.404	7.32e-14
drug:age	4	6.6	1.6	0.437	0.781
sex:age	2	4.7	2.3	0.621	0.540
drug:sex:age	4	27.0	6.8	1.795	0.139
Residuals	72	270.8	3.8		



- is highest order interaction significant?
 - yes: ignore all other effects
 - no: look at set of next highest order interactions
- A x B x C interaction asks “is the 2-way A x B interaction different across levels of C?”
- A x B interactions are averaged over levels of C
- A main effect is averaged over levels of B and C

an example of a 3-way interaction




- the 2-way **drug:sex** interaction is **different across levels of age**
- for infants there is no **drug:sex** interaction
- for young and old **there is a two-way drug:sex** interaction
 - **drug** increases memory for females but not for males

3-Way Factorial ANOVA

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	384.7	192.4	51.148	1.51e-14
sex	1	570.4	570.4	151.656	< 2e-16
age	2	1399.9	699.9	186.113	< 2e-16
drug:sex	2	356.6	178.3	47.404	7.32e-14
drug:age	4	6.6	1.6	0.437	0.781
sex:age	2	4.7	2.3	0.621	0.540
drug:sex:age	4	27.0	6.8	1.795	0.139
Residuals	72	270.8	3.8		

- **drug:sex:age** interaction is not significant
- the **drug:sex** interaction is significant
- the **drug:sex** interaction is the same for all levels of **age**
- **age** doesn't appear in **any** of the interaction terms
- the **age** main effect is significant



- our Follow-up Plan:
 1. follow up the main effect of **age**
 2. follow up **drug:sex** interaction, ignoring **age**
- (ignore the **drug** and **age** main effects)

3-Way Factorial ANOVA

- follow up the main effect of **age**

```
1 library(emmeans)
2 ageMM <- emmeans(my.anova, specs = ~ age)
3 pairs(ageMM, adjust="holm")
```

contrast	estimate	SE	df	t.ratio	p.value
infant - young	-5.21	0.501	72	-10.399	<.0001
infant - old	-9.65	0.501	72	-19.273	<.0001
young - old	-4.44	0.501	72	-8.874	<.0001

Results are averaged over the levels of: drug, sex
P value adjustment: holm method for 3 tests


- there is a significant difference in memory score between the infant and young groups, $t(72)=-10.4$, $p<.0001$
- there is a significant difference in memory score between the infant and old groups, $t(72)=-19.3$, $p<.0001$
- there is a significant difference in memory score between the young and old groups, $t(72)=-8.9$, $p<.0001$

age	emmean	SE	df	lower.CL	upper.CL
infant	103	0.354	72	102	103
young	108	0.354	72	107	108
old	112	0.354	72	112	113

Results are averaged over the levels of: drug, sex
Confidence level used: 0.95

► Code

Memory Data



3-Way Factorial ANOVA

- follow up the **drug:sex** interaction
- simple main effects of **drug**
- main effect of Drug for “Female” level of **sex**:

```
1 memfemale <- memdata %>% filter(sex=="Female")
2 female.anova <- aov(memory ~ drug, data=memfemale)
3 summary(female.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	738.6	369.3	17.51	2.95e-06
Residuals	42	885.7	21.1		

- main effect of Drug for “Male” level of **sex**:


```
1 memmale <- memdata %>% filter(sex=="Male")
2 male.anova <- aov(memory ~ drug, data=memmale)
3 summary(male.anova)
```

	Df	Sum Sq	Mean Sq	F value	Pr(>F)
drug	2	2.7	1.356	0.069	0.933
Residuals	42	823.2	19.600		

- so let's follow up the main effect of **drug** in Females, with pairwise posthoc tests

► Code

Memory Data



- we just did one one-way ANOVA using the subset of data for Females and another using the subset of data for Males


3-Way Factorial ANOVA

- follow up the **drug:sex** interaction
- pairwise posthoc tests of the main effect of **drug** in Females
- using the **female.anova** object (which was made using only data for Females)

```
1 drugMfemale <- emmeans(female.anova, specs = ~
2 pairs(drugMfemale, adjust="holm")
```

contrast	estimate	SE	df	t.ratio	p.value
Placebo - Low Dose	-5.38	1.68	42	-3.211	0.0051
Placebo - High Dose	-9.91	1.68	42	-5.911	<.0001
Low Dose - High Dose	-4.53	1.68	42	-2.699	0.0100

P value adjustment: holm method for 3 tests



3-Way Factorial ANOVA


- follow up the **drug:sex** interaction
- pairwise posthoc tests of the main effect of **drug** in Females
- using **emmeans** with the **my.anova** 3-way ANOVA gives us a more powerful test because it uses the error term from the 3-factor ANOVA

```
1 emmeans(my.anova, specs = ~drug:sex) %>%  
2 pairs(simple="drug", adjust="holm")
```

```
sex = Male:  
contrast      estimate    SE df t.ratio p.value  
Placebo - Low Dose    -0.582 0.708 72  -0.822  1.0000  
Placebo - High Dose   -0.160 0.708 72  -0.227  1.0000  
Low Dose - High Dose    0.422 0.708 72   0.595  1.0000
```

```
sex = Female:  
contrast      estimate    SE df t.ratio p.value  
Placebo - Low Dose    -5.385 0.708 72  -7.604 <.0001  
Placebo - High Dose   -9.911 0.708 72 -13.996 <.0001  
Low Dose - High Dose   -4.527 0.708 72  -6.392 <.0001
```

```
Results are averaged over the levels of: age  
P value adjustment: holm method for 3 tests
```



- Like when we did simple main effects in our 2x2 design earlier, and we computed a custom F-test using the error term from the full ANOVA